Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
Volume: 382, Issue: 25, Pages: 2419 - 2430
Published: Jun 18, 2020
Abstract
Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate consisting of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor. The drug may have efficacy in patients with HER2-positive advanced gastric...
Paper Details
Title
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
Published Date
Jun 18, 2020
Volume
382
Issue
25
Pages
2419 - 2430
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History